Global perspectives on the three criteria for premature ejaculation: An observational study of ejaculatory latency, ejaculatory control and bother/distress

Andrologia ◽  
2020 ◽  
Vol 52 (11) ◽  
Author(s):  
Philippe Cote‐Leger ◽  
David L. Rowland
Keyword(s):  
Observational Study ◽  
Premature Ejaculation ◽  
Global Perspectives ◽  
Ejaculatory Latency ◽  
Ejaculatory Control

scholarly journals Observational study on the effects of a topical formulation in patients with premature ejaculation

2020 ◽  
Vol 92 (4) ◽  
Author(s):  
Giuseppe Quarto ◽  
Luigi Castaldo ◽  
Giovanni Grimaldi ◽  
Alessandro Izzo ◽  
Raffaele Muscariello ◽  
...  
Keyword(s):  
Sexual Dysfunction ◽  
Observational Study ◽  
Sexual Satisfaction ◽  
Premature Ejaculation ◽  
Clinical History ◽  
Diagnostic Approach ◽  
Latency Time ◽  
Topical Formulation ◽  
Ejaculatory Latency

Premature ejaculation (PE) has been defined as the inability to control or delay ejaculation, resulting in dissatisfaction or distress of the patient. Although PE is the most frequent sexual dysfunction, it is still underdiagnosed. An accurate clinical history is the best diagnostic approach that, in the majority of cases, is enough to differentiate between primary and acquired PE. Nowadays, treatment is not curative but is effective in increasing the intravaginal ejaculatory latency time (IELT), improving the sexual satisfaction of the couple [...].

ORIGINAL RESEARCH—EJACULATORY DISORDERS: Premature Ejaculation: An Observational Study of Men and Their Partners

2005 ◽  
Vol 2 (3) ◽  
pp. 358-367 ◽  
Author(s):  
Donald L. Patrick ◽  
Stanley E. Althof ◽  
Jon L. Pryor ◽  
Raymond Rosen ◽  
David L. Rowland ◽  
...  
Keyword(s):  
Observational Study ◽  
Premature Ejaculation ◽  
Original Research

scholarly journals Fortacin™ Spray for the Treatment of Premature Ejaculation

2017 ◽  
Vol 84 (2_suppl) ◽  
pp. 1-10 ◽  
Author(s):  
Hartmut Porst ◽  
Andrea Burri
Keyword(s):  
Large Scale ◽  
Premature Ejaculation ◽  
Glans Penis ◽  
The European Union ◽  
Ejaculatory Latency ◽  
Adult Men ◽  
Interpersonal Distress ◽  
The United Kingdom ◽  
Metered Dose ◽  
Increased Sensitivity

Premature ejaculation (PE) is a common complaint of male sexual dysfunction affecting men and their partners and consequently causing significant personal and interpersonal distress. Increased sensitivity of the glans penis and abnormalities of the afferent-efferent reflex pathway within the ejaculatory process are involved in the occurrence of PE. Drugs that either selectively reduce penile sensitization or modify the afferent-efferent reflex are well established therapeutic options for PE. Fortacin™ is the first topical treatment to be officially approved for the treatment of primary PE in adult men, and is mentioned as an experimental aerosol (as TEMPE) in the current European Association of Urology guidelines. It was approved for use in the European Union and launched in the United Kingdom in November 2016. Fortacin™ is a eutectic-like mixture of lidocaine 150 mg/mL and prilocaine 50 mg/mL that meets the requirements of an ideal treatment for PE because it is fast acting (within 5 minutes), has durable effects, can be easily used “on-demand”, and shows minimal side-effects. The metered-dose spray delivery system allows the desensitizing agents to be deposited in a dose-controlled, concentrated film onto the glans penis consequently reducing its sensitivity. This is translated into a delaying of the ejaculatory latency time without adversely affecting the sensation of ejaculation and orgasmic pleasure. The efficacy and safety of Fortacin™ have been proven by means of increased ejaculatory latency, control, and sexual satisfaction in large scale studies demonstrating the significant benefits for both patients and their partners.

Sign in / Sign up

Export Citation Format

Share Document